Several themes were selected from those that marked the year 2016. The analysis of registries with «real life» data regarding the use of direct oral anticoagulants is reassuring and overall confirm the data of the pivotal studies. We also present the validation of a prediction rule for risk stratification of thromboembolism recurrence and duration of anticoagulation after an unprovoked event. In addition, new data shed light on the treatment of distal vein thrombosis. We also address the issue of venous thromboembolism risk related to oral contraceptives and the issue of genetic testing prior prescription, and finally present a new factor VIII recently available for the treatment of patients with acquired hemophilia A.